Previous 10 | Next 10 |
home / stock / adilw / adilw news
CHARLOTTESVILLE, VA / ACCESSWIRE / June 13, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the further strengthening of its intellectual property (IP) portfolio, as i...
Adial Reaffirms on Track to Commence Phase 3 Trial in Q3 2019 CHARLOTTESVILLE, VA / ACCESSWIRE / June 6, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) www.adialpharma.com , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, an...
CHARLOTTESVILLE, VA / ACCESSWIRE / May 7, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) www.adialpharma.com , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that it has entered into a collaboration agreement with ...
CHARLOTTESVILLE, VA / ACCESSWIRE / April 30 , 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced William Stilley, President and Chief Executive Officer, is scheduled ...
World-renowned addiction doctor talks about combating alcohol and opioid addiction during National Alcohol Awareness Month CHARLOTTESVILLE, VA / ACCESSWIRE / April 22 , 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on t...
Adial to Advance Corporate Partnerships; Licensing and M&A Opportunities CHARLOTTESVILLE, VA / ACCESSWIRE / April 11, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, t...
Lecture to focus on pharmacogenic treatment personalization for alcohol use disorder CHARLOTTESVILLE, VA / ACCESSWIRE / April 4, 2019 / Adial Pharmaceuticals Inc. , (NADSAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction,...
CHARLOTTESVILLE, VA / ACCESSWIRE / April 3, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole A. Johnson, M.D., DSc., M.B., ChB., M.Phil., DFAPA, FRCPsych,...
CHARLOTTESVILLE, VA / ACCESSWIRE / March 26, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; NASDAQ: ADILW), a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced that Bankole A. Johnson, M.D., DSc., M.B., ChB., M.Phil., DFAPA...
CHARLOTTESVILLE, VA / ACCESSWIRE / March 25, 2019 / Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, announced today that it filed a Registration Statement on Form S-1 on March 22, 2019, to ...
News, Short Squeeze, Breakout and More Instantly...
Adial Pharmaceuticals Inc Warrant Company Name:
ADILW Stock Symbol:
NASDAQ Market:
Adial Pharmaceuticals Inc Warrant Website:
GLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorder...
GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,...
Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studies and support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va., June 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: A...